International Journal of Medicine and Data

Objective To analyze the clinical efficacy of enoxaparin sodium in the treatment of preeclampsia. Methods The study subjects were 100 preeclamptic patients admitted to our hospital (admission time range: January 2023 to January 2024). All preeclampsia patients volunteered to participate in the study and divided 100 patients into 2 groups: control group, observation group and 50 cases / group. Control group —— labeolol; observation group —— enoxaparin sodium adjuvant labeolol. Compared the clinical index, coagulation function index, and maternal and infant outcomes before and after treatment in group 2 of preeclamptic patients. Results Before treatment, blood pressure and heart rate comparison of preeclamptic patients: P> 0.05; after treatment, the preeclamptic patients reached normal levels, compared with the control group (P <0.05); before treatment, coagulation comparison of preeclamptic patients: P> 0.05; after treatment, the observation group improved significantly better than the control group, data comparison (P <0.05). The incidence of preterm birth, postpartum hemorrhage and neonatal asphyxia in the observation group were lower than that in the control group, and the difference was: P <0.05. Conclusion The treatment of enoxaparin sodium assisted alcohol in patients with preeclampsia can significantly reduce blood pressure, effectively improve coagulation function, reduce adverse pregnancy outcomes, improve clinical safety and has high effect value.

Enoxaparin sodium; Laelol; Preeclampsia; Clinical efficacy